Healthcare - Biotechnology - NASDAQ - US
$ 9.905
-11.1 %
$ 618 M
Market Cap
-1.31
P/E
CASH FLOW STATEMENT
-7.57 M
OPERATING CASH FLOW
-30.5 M
INVESTING CASH FLOW
116 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Immunome, Inc.
| Net Income | -107 M |
| Depreciation & Amortization | 728 K |
| Capital Expenditures | -831 K |
| Stock-Based Compensation | 6.22 M |
| Change in Working Capital | 12 M |
| Others | 92.9 M |
| Free Cash Flow | -8.4 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (106.8) | (36.9) | (24.7) | (17.8) | (10.4) | (7.8) |
| Depreciation & Amortization | 0.7 | 0.6 | 0.8 | 0.8 | 0.6 | 0.5 |
| Deferred Income Tax | 0 | (7.3) | (0.5) | 5.5 | 0 | 0 |
| Stock Based Compensation | 6.2 | 5.3 | 3.4 | 0.6 | 14 K | 11 K |
| Other Operating Activities | 80.3 | 7.3 | 4 K | 2 K | 3 K | 9 K |
| Change in Working Capital | 12.0 | 2.2 | 2.8 | (1.2) | 0.2 | (0.1) |
| Cash From Operations | (7.6) | (28.7) | (18.2) | (12.1) | (9.6) | (7.4) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (0.8) | (0.2) | 79 K | (0.6) | (0.2) | (0.2) |
| Other Items | (29.7) | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (30.5) | (0.2) | 79 K | (0.6) | (0.2) | (0.2) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 35 K | 0 |
| Total Debt Repaid | 0 | 0 | (0.1) | 49 K | 6.2 | (0.6) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 116.4 | 32 K | 0.7 | 5.0 | 4.6 | 0 |
| Cash From Financing Activities | 116.4 | 32 K | 27.8 | 49.9 | 10.8 | (0.6) |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 78.4 | (28.9) | 9.5 | 37.2 | 0.9 | (8.2) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (8.4) | (28.9) | (18.3) | (12.7) | (9.8) | (7.6) |